Literature DB >> 7875483

Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study.

M Borzio1, S Bruno, M Roncalli, G C Mels, G Ramella, F Borzio, G Leandro, E Servida, M Podda.   

Abstract

BACKGROUND/AIMS: In humans, the role of liver cell dysplasia as a preneoplastic lesion is still debated. A prospective, long-term, multicenter study was performed to establish whether liver cell dysplasia in cirrhosis is associated with an increased risk for hepatocellular carcinoma (HCC).
METHODS: A cohort of 307 consecutive patients in whom liver cirrhosis was diagnosed by histology was investigated for development of HCC at 6-month intervals by ultrasonography and determination of alpha-fetoprotein levels.
RESULTS: At enrollment, liver cell dysplasia was found in 75 patients (24%) and in 53% (P < 0.01) of those positive for hepatitis B surface antigen (HBsAg). After a mean follow-up of 46 months, HCC was detected in 45 cases, and it was significantly more frequent in patients with liver cell dysplasia (P < 0.01) and HBsAg-serum positivity (P < 0.01). Multivariate analysis showed that liver cell dysplasia was the most important risk factor correlated with HCC development. HBsAg positivity and age over 60 years were also independent risk factors for HCC.
CONCLUSIONS: These results indicate that liver cell dysplasia is a major risk factor for HCC, and it should be looked for carefully by pathologists in liver biopsy specimens to identify patients requiring more intensive observation.

Entities:  

Mesh:

Year:  1995        PMID: 7875483     DOI: 10.1016/0016-5085(95)90455-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

1.  Expression of insulin like growth factor II and its receptor in hepatocellular carcinogenesis.

Authors:  Z R Fan; D H Yang; J Cui; H R Qin; C C Huang
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

Review 3.  [1997 gastroenterology update--II].

Authors:  W Fischbach; V Gross; J Schölmerich; C Ell; P Layer; W E Fleig
Journal:  Med Klin (Munich)       Date:  1998-03-15

4.  Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Authors:  L Bolondi; S Sofia; S Siringo; S Gaiani; A Casali; G Zironi; F Piscaglia; L Gramantieri; M Zanetti; M Sherman
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

5.  Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes.

Authors:  Peter J Kneuertz; Aram Demirjian; Amin Firoozmand; Celia Corona-Villalobos; Nikhil Bhagat; Joseph Herman; Andrew Cameron; Ahmet Gurakar; David Cosgrove; Michael A Choti; Jean-Francois H Geschwind; Ihab R Kamel; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2012-04-03       Impact factor: 5.344

6.  Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.

Authors:  Mauro Montalbano; Cristiana Rastellini; Joshua T McGuire; Janika Prajapati; Ali Shirafkan; Renza Vento; Luca Cicalese
Journal:  Cell Oncol (Dordr)       Date:  2017-12-04       Impact factor: 6.730

7.  Chromosomal abnormalities in liver cell dysplasia detected by comparative genomic hybridisation.

Authors:  A Marchio; B Terris; M Meddeb; P Pineau; A Duverger; P Tiollais; A Bernheim; A Dejean
Journal:  Mol Pathol       Date:  2001-08

8.  Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Seung In Seo; Hyoung Su Kim; Won Jin Kim; Woon Geon Shin; Doo Jin Kim; Kyung Ho Kim; Myoung Kuk Jang; Jin Heon Lee; Joo Seop Kim; Hak Yang Kim; Dong Joon Kim; Myung Seok Lee; Choong Kee Park
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

9.  Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis.

Authors:  M Borzio; D Trerè; F Borzio; A R Ferrari; S Bruno; M Roncalli; G Colloredo; G Leandro; F Oliveri; M Derenzini
Journal:  Mol Pathol       Date:  1998-04

Review 10.  Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.

Authors:  Cristina Della Corte; Alessio Aghemo; Massimo Colombo
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.